<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Pro | wechat-feeds</title><link>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</link><description>聚焦生物医药前沿，洞察研发投资风向</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 05 Apr 2021 21:29:01 +0800</pubDate><image><url>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Pro | wechat-feeds</title><link>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>世界首个基于CRISPR/Cas9基因编辑的双靶点通用型CAR-T细胞治疗B急淋的临床研究成果</title><link>https://mp.weixin.qq.com/s/fWO1sXyzHZIE7EwLdo8Xcw</link><description></description><content:encoded><![CDATA[世界首个基于CRISPR/Cas9基因编辑的双靶点通用型CAR-T细胞治疗B急淋的临床研究成果]]></content:encoded><pubDate>Mon, 05 Apr 2021 20:58:56 +0800</pubDate></item><item><title>2020年全球药品销售额TOP100</title><link>https://mp.weixin.qq.com/s/0hYDaOsNGpPh9uHx4oetKA</link><description></description><content:encoded><![CDATA[2020年全球药品销售额TOP100]]></content:encoded><pubDate>Sun, 04 Apr 2021 20:58:49 +0800</pubDate></item><item><title>PD-1/PD-L1联合治疗全梳理：理想很丰满，现实很骨感</title><link>https://mp.weixin.qq.com/s/jKneZj763iHZFdWDfmvJQA</link><description></description><content:encoded><![CDATA[PD-1/PD-L1联合治疗全梳理：理想很丰满，现实很骨感]]></content:encoded><pubDate>Sat, 03 Apr 2021 20:58:57 +0800</pubDate></item><item><title>林欣点评 | 攻克实体瘤新利器——STAR-T</title><link>https://mp.weixin.qq.com/s/R2gTTU9ye5ZmZrA7Y3waVg</link><description></description><content:encoded><![CDATA[林欣点评 | 攻克实体瘤新利器——STAR-T]]></content:encoded><pubDate>Fri, 02 Apr 2021 20:58:46 +0800</pubDate></item><item><title>Science：人类癌症与微生物组「图鉴」</title><link>https://mp.weixin.qq.com/s/zY6j5gHlDnHsZQF7arz3UQ</link><description></description><content:encoded><![CDATA[Science：人类癌症与微生物组「图鉴」]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:59:20 +0800</pubDate></item><item><title>开发表观遗传调控疗法！Omega 完成1.26亿美元C轮融资，首个产品瞄准肝癌</title><link>https://mp.weixin.qq.com/s/hvnuItEzJuM_3MrRKwFf9Q</link><description></description><content:encoded><![CDATA[开发表观遗传调控疗法！Omega 完成1.26亿美元C轮融资，首个产品瞄准肝癌]]></content:encoded><pubDate>Wed, 31 Mar 2021 21:00:15 +0800</pubDate></item><item><title>杨大俊点评 | 颠覆认知：p53“铁搭档”MDM2，竟是抗癌帮手</title><link>https://mp.weixin.qq.com/s/rKGa0-UhtC_cXhbZXj8y3Q</link><description></description><content:encoded><![CDATA[杨大俊点评 | 颠覆认知：p53“铁搭档”MDM2，竟是抗癌帮手]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:00:59 +0800</pubDate></item><item><title>三阴性乳腺癌治疗新靶点——FGD5 | 中国科学家Science子刊最新成果</title><link>https://mp.weixin.qq.com/s/jvYTHRCEqPaz7k94hHwlUQ</link><description></description><content:encoded><![CDATA[三阴性乳腺癌治疗新靶点——FGD5 | 中国科学家Science子刊最新成果]]></content:encoded><pubDate>Mon, 29 Mar 2021 21:21:54 +0800</pubDate></item><item><title>PROTAC新应用：成功降解CDK2 | Nature子刊最新成果</title><link>https://mp.weixin.qq.com/s/yqYqnT4dvDUltnnx4Q3neQ</link><description></description><content:encoded><![CDATA[PROTAC新应用：成功降解CDK2 | Nature子刊最新成果]]></content:encoded><pubDate>Sun, 28 Mar 2021 20:57:56 +0800</pubDate></item><item><title>PD-1抗体“超强搭档”：联合长效IL-2融合蛋白，小鼠肿瘤完全缓解</title><link>https://mp.weixin.qq.com/s/_6vtYHY9fV0SMVCb88yvMw</link><description></description><content:encoded><![CDATA[PD-1抗体“超强搭档”：联合长效IL-2融合蛋白，小鼠肿瘤完全缓解]]></content:encoded><pubDate>Sat, 27 Mar 2021 21:00:48 +0800</pubDate></item></channel></rss>